Business Context and Reporting Period
This Form 8-K Current Report was filed by IRIDEX CORPORATION on December 16, 2009. The filing reports a corporate governance event: the appointment of a new member to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The material change reported is the appointment of Ruediger Naumann-Etienne to the Board of Directors effective December 16, 2009. Dr. Naumann-Etienne brings significant experience in the medical device sector, including roles as Managing Director of Intertec Group, Chairman of Cardiac Science, and former leadership positions at Quinton Cardiology Systems, OEC Medical Systems, and Diasonics.
Guidance, Outlook, and Compensation
There is no financial guidance or outlook provided in this filing. The document details the compensatory arrangements for the new director:
- Meeting Fees: $1,500 for each Board meeting attended.
- Initial Equity Grant: An option to purchase 15,000 shares of common stock at fair market value, vesting ratably over 36 months.
- Annual Equity Grant: An additional option to purchase 5,000 shares annually, vesting ratably over 12 months.
- Indemnification: Expected to execute the Company's standard form of indemnification agreement.
Investor Verification Checklist
- Verify the effective date of Dr. Naumann-Etienne's appointment (December 16, 2009).
- Review the attached press release (Exhibit 99.1) for additional context on the appointment.
- Confirm the vesting schedule details for the initial 15,000 share option grant.
- Check the Company's 2009 annual proxy statement for the full text of the non-employee director compensation arrangements.